Table 3.
Personal and laboratory characteristics of 29 corticosteroid resistant ITP patients who received consecutive low-dose decitabine therapy.
| Total (n = 29) | R (n = 15) | NR (n = 14) | P (R vs. NR) | |
|---|---|---|---|---|
| Age (years), median (range) | 43 (15–84) | 39 (15–65) | 49 (20–84) | 0.275 a |
| Female, % (n) | 69 (20) | 67 (10) | 71 (10) | 0.362 b |
| ITP duration (months), median (range) | 3 (1–12) | 3 (1–12) | 4 (1–12) | 0.276 a |
| Previous therapies, % (n) | ||||
| Corticosteroid | 100 (29) | 100 (15) | 100 (14) | – |
| rhTPO | 52 (15) | 40 (6) | 64 (9) | 0.191 b |
| Eltrombopag | 17 (5) | 13 (2) | 21 (3) | 0.564 b |
| Intravenous Immunoglobulin | 41 (12) | 40 (6) | 43 (6) | 0.597 b |
|
Platelet count (109/L),
median (range) |
||||
| At enrollment | 7 (1–65) | 6 (1–65) | 6 (1–21) | 0.442 a |
| At end of observation | 35 (0–266) | 119 (35–266) | 7 (0–35) | <0.001 a |
|
Bleeding score,
median (range) |
||||
| At enrollment | 3 (0–11) | 3 (0–6) | 3 (0–11) | 0.946 a |
| At end of observation | 0 (0–3) | 0 (0–0) | 2 (0–3) | <0.001 a |
|
ICAM-1 (ng/ml),
median (IQR) |
||||
| At enrollment | 92 (59–121) | 80 (50–92) | 121 (77–152) | 0.005 a |
| At end of observation | 103 (70–136) | 75 (66–108) | 123 (100–157) | 0.026 a |
|
Angiopoietin-2 (pg/ml),
median (IQR) |
||||
| At enrollment | 1,559 (1,091–1,716) | 1,291 (866–1,007) | 1,633 (1262–1,837) | 0.138 a |
| At end of observation | 1,366 (1,027–1,778) | 1,102 (999–1,436) | 1,650(1167–1,852) | 0.163 a |
a
Mann–Whitney U test.
b
Fisher exact or chi-square test.
R, responder; NR, non-responder; IQR, interquartile range.